- Home
- BIVI vs ACHL Comparison
BIVI vs ACHL Comparison
Compare BIVI & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- ACHL
- Stock Information
- Founded
- BIVI 2013
- ACHL 2016
- Country
- BIVI United States
- ACHL United Kingdom
- Employees
- BIVI N/A
- ACHL N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIVI Health Care
- ACHL Health Care
- Exchange
- BIVI Nasdaq
- ACHL Nasdaq
- Market Cap
- BIVI 49.8M
- ACHL 46.8M
- IPO Year
- BIVI N/A
- ACHL 2021
- Fundamental
- Price
- BIVI $2.05
- ACHL $1.15
- Analyst Decision
- BIVI Strong Buy
- ACHL Buy
- Analyst Count
- BIVI 1
- ACHL 2
- Target Price
- BIVI $30.00
- ACHL $4.00
- AVG Volume (30 Days)
- BIVI 1.1M
- ACHL 266.6K
- Earning Date
- BIVI 02-11-2025
- ACHL 11-14-2024
- Dividend Yield
- BIVI N/A
- ACHL N/A
- EPS Growth
- BIVI N/A
- ACHL N/A
- EPS
- BIVI N/A
- ACHL N/A
- Revenue
- BIVI N/A
- ACHL N/A
- Revenue This Year
- BIVI N/A
- ACHL N/A
- Revenue Next Year
- BIVI N/A
- ACHL N/A
- P/E Ratio
- BIVI N/A
- ACHL N/A
- Revenue Growth
- BIVI N/A
- ACHL N/A
- 52 Week Low
- BIVI $1.04
- ACHL $0.63
- 52 Week High
- BIVI $33.10
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- BIVI 41.87
- ACHL 57.79
- Support Level
- BIVI $1.90
- ACHL $1.12
- Resistance Level
- BIVI $2.27
- ACHL $1.18
- Average True Range (ATR)
- BIVI 0.20
- ACHL 0.05
- MACD
- BIVI 0.01
- ACHL -0.00
- Stochastic Oscillator
- BIVI 22.19
- ACHL 44.44
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.